Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells

OncoImmunology

Volumn 5, Issue 10, 2016, Pages

  Antonangeli, Fabrizio ^a   Soriani, Alessandra ^a   Ricci, Biancamaria ^a   Ponzetta, Andrea ^a,d   Benigni, Giorgia ^a   Morrone, Stefania ^b   Bernardini, Giovanni ^a,c   Santoni, Angela ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS NEUROMED   (Italy)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

DNAM 1; immunomodulation; melphalan; multiple myeloma; natural killer cell; NKG2D; senescence

Indexed keywords

BETA GALACTOSIDASE; CD69 ANTIGEN; LIGAND; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELPHALAN;

ANIMAL CELL; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRDU ASSAY; CELL ACTIVITY; CELL CYCLE ASSAY; CONTROLLED STUDY; CYTOFLUOROMETRY; DEGRANULATION ASSAY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MOLECULAR RECOGNITION; MOUSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING;

EID: 84988726239     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1218105     Document Type: Article

References (69)

1. I.B.Roninson. Tumor cell senescence in cancer treatment. Cancer Res 2003; 63:2705-15; PMID:12782571
2. I.B.Roninson, E.V.Broude, B.D.Chang. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 2001; 4:303-13; PMID:11991684; http://dx.doi.org/10.1054/drup.2001.0213
3. R.H.te Poele, A.L.Okorokov, L.Jardine, J.Cummings, S.P.Joel. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 2002; 62:1876-83; PMID:11912168
4. J.Campisi, F.d'Adda di Fagagna. Cellular senescence:when bad things happen to good cells. Nat Rev Mol Cell Biol 2007; 8:729-40; PMID:17667954; http://dx.doi.org/10.1038/nrm2233
5. L.Hayflick, P.S.Moorhead. The serial cultivation of human diploid cell strains. Exp Cell Res 1961; 25:585-621; PMID:13905658; http://dx.doi.org/10.1016/0014-4827(61)90192-6
6. T.Kuilman, C.Michaloglou, W.J.Mooi, D.S.Peeper. The essence of senescence. Genes Dev 2010; 24:2463-79; PMID:21078816; http://dx.doi.org/10.1101/gad.1971610
7. D.Munoz-Espin, M.Serrano. Cellular senescence:from physiology to pathology. Nat Rev Mol Cell Biol 2014; 15:482-96; PMID:24954210; http://dx.doi.org/10.1038/nrm3823
8. D.Munoz-Espin, M.Canamero, A.Maraver, G.Gomez-Lopez, J.Contreras, S.Murillo-Cuesta, A.Rodriguez-Baeza, I.Varela-Nieto, J.Ruberte, M.Collado et al. Programmed cell senescence during mammalian embryonic development. Cell 2013; 155:1104-18; PMID:24238962; http://dx.doi.org/10.1016/j.cell.2013.10.019
9. M.Storer, A.Mas, A.Robert-Moreno, M.Pecoraro, M.C.Ortells, V.Di Giacomo, R.Yosef, N.Pilpel, V.Krizhanovsky, J.Sharpe et al. Senescence is a developmental mechanism that contributes to embryonic growth and patterning. Cell 2013; 155:1119-30; PMID:24238961; http://dx.doi.org/10.1016/j.cell.2013.10.041
10. M.Demaria, N.Ohtani, S.A.Youssef, F.Rodier, W.Toussaint, J.R.Mitchell, R.M.Laberge, J.Vijg, H.Van Steeg, M.E.Dolle et al. An essential role for senescent cells in optimal wound healing through secretion of PDGF-AA. Dev Cell 2014; 31:722-33; PMID:25499914; http://dx.doi.org/10.1016/j.devcel.2014.11.012
11. M.Serrano. Senescence helps regeneration. Dev Cell 2014; 31:671-2; PMID:25535913; http://dx.doi.org/10.1016/j.devcel.2014.12.007
12. L.Hoenicke, L.Zender. Immune surveillance of senescent cells–biological significance in cancer- and non-cancer pathologies. Carcinogenesis 2012; 33:1123-6; PMID:22470164; http://dx.doi.org/10.1093/carcin/bgs124
13. M.Collado, M.Serrano. Senescence in tumours:evidence from mice and humans. Nat Rev Cancer 2010; 10:51-7; PMID:20029423; http://dx.doi.org/10.1038/nrc2772
14. P.Kahlem, B.Dorken, C.A.Schmitt. Cellular senescence in cancer treatment:friend or foe? J Clin Invest 2004; 113:169-74; PMID:14722606; http://dx.doi.org/10.1172/JCI20784
15. L.Zitvogel, L.Apetoh, F.Ghiringhelli, F.Andre, A.Tesniere, G.Kroemer. The anticancer immune response:indispensable for therapeutic success? J Clin Invest 2008; 118:1991-2001; PMID:18523649; http://dx.doi.org/10.1172/JCI35180
16. L.Zitvogel, L.Apetoh, F.Ghiringhelli, G.Kroemer. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216
17. E.Vivier, D.H.Raulet, A.Moretta, M.A.Caligiuri, L.Zitvogel, L.L.Lanier, W.M.Yokoyama, S.Ugolini. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx.doi.org/10.1126/science.1198687
18. J.D.Coudert, W.Held. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006; 16:333-43; PMID:16914326; http://dx.doi.org/10.1016/j.semcancer.2006.07.008
19. S.Gilfillan, C.J.Chan, M.Cella, N.M.Haynes, A.S.Rapaport, K.S.Boles, D.M.Andrews, M.J.Smyth, M.Colonna. DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors. J Exp Med 2008; 205:2965-73; PMID:19029380; http://dx.doi.org/10.1084/jem.20081752
20. L.L.Lanier. NK cell recognition. Annu Rev Immunol 2005; 23:225-74; PMID:15771571; http://dx.doi.org/10.1146/annurev.immunol.23.021704.115526
21. L.Moretta, C.Bottino, D.Pende, R.Castriconi, M.C.Mingari, A.Moretta. Surface NK receptors and their ligands on tumor cells. Semin Immunol 2006; 18:151-8; PMID:16730454; http://dx.doi.org/10.1016/j.smim.2006.03.002
22. D.H.Raulet. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003; 3:781-90; PMID:14523385; http://dx.doi.org/10.1038/nri1199
23. A.Iannello, D.H.Raulet. Immune surveillance of unhealthy cells by natural killer cells. Cold Spring Harb Symp Quant Biol 2013; 78:249-57; PMID:24135717; http://dx.doi.org/10.1101/sqb.2013.78.020255
24. D.H.Raulet, N.Guerra. Oncogenic stress sensed by the immune system:role of natural killer cell receptors. Nat Rev Immunol 2009; 9:568-80; PMID:19629084; http://dx.doi.org/10.1038/nri2604
25. A.Soriani, C.Fionda, B.Ricci, M.L.Iannitto, M.Cippitelli, A.Santoni. Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma. Oncoimmunology 2013; 2:e26663; PMID:24498552; http://dx.doi.org/10.4161/onci.26663
26. V.Krizhanovsky, M.Yon, R.A.Dickins, S.Hearn, J.Simon, C.Miething, H.Yee, L.Zender, S.W.Lowe. Senescence of activated stellate cells limits liver fibrosis. Cell 2008; 134:657-67; PMID:18724938; http://dx.doi.org/10.1016/j.cell.2008.06.049
27. A.Sagiv, A.Biran, M.Yon, J.Simon, S.W.Lowe, V.Krizhanovsky. Granule exocytosis mediates immune surveillance of senescent cells. Oncogene 2013; 32:1971-7; PMID:22751116; http://dx.doi.org/10.1038/onc.2012.206
28. A.Soriani, A.Zingoni, C.Cerboni, M.L.Iannitto, M.R.Ricciardi, V.Di Gialleonardo, M.Cippitelli, C.Fionda, M.T.Petrucci, A.Guarini et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. Blood 2009; 113:3503-11; PMID:19098271; http://dx.doi.org/10.1182/blood-2008-08-173914
29. A.Iannello, D.H.Raulet. Immunosurveillance of senescent cancer cells by natural killer cells. Oncoimmunology 2014; 3:e27616; PMID:24800169; http://dx.doi.org/10.4161/onci.27616
30. A.Iannello, T.W.Thompson, M.Ardolino, S.W.Lowe, D.H.Raulet. p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J Exp Med 2013; 210:2057-69; PMID:24043758; http://dx.doi.org/10.1084/jem.20130783
31. A.Palumbo, K.Anderson. Multiple myeloma. N Engl J Med 2011; 364:1046-60; PMID:21410373; http://dx.doi.org/10.1056/NEJMra1011442
32. E.Carbone, P.Neri, M.Mesuraca, M.T.Fulciniti, T.Otsuki, D.Pende, V.Groh, T.Spies, G.Pollio, D.Cosman et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005; 105:251-8; PMID:15328155; http://dx.doi.org/10.1182/blood-2004-04-1422
33. Y.M.El-Sherbiny, J.L.Meade, T.D.Holmes, D.McGonagle, S.L.Mackie, A.W.Morgan, G.Cook, S.Feyler, S.J.Richards, F.E.Davies et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 2007; 67:8444-9; PMID:17875681; http://dx.doi.org/10.1158/0008-5472.CAN-06-4230
34. R.Garcia-Sanz, M.Gonzalez, A.Orfao, M.J.Moro, J.M.Hernandez, D.Borrego, M.Carnero, F.Casanova, A.Barez, R.Jimenez et al. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications. Br J Haematol 1996; 93:81-8; PMID:8611480; http://dx.doi.org/10.1046/j.1365-2141.1996.4651006.x
35. M.Jinushi, M.Vanneman, N.C.Munshi, Y.T.Tai, R.H.Prabhala, J.Ritz, D.Neuberg, K.C.Anderson, D.R.Carrasco, G.Dranoff. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A 2008; 105:1285-90; PMID:18202175; http://dx.doi.org/10.1073/pnas.0711293105
36. V.Jurisic, T.Srdic, G.Konjevic, O.Markovic, M.Colovic. Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 2007; 24:312-7; PMID:17873307; http://dx.doi.org/10.1007/s12032-007-0007-y
37. A.Osterborg, B.Nilsson, M.Bjorkholm, G.Holm, H.Mellstedt. Natural killer cell activity in monoclonal gammopathies:relation to disease activity. Eur J Haematol 1990; 45:153-7; PMID:1699786; http://dx.doi.org/10.1111/j.1600-0609.1990.tb00443.x
38. C.Fionda, M.P.Abruzzese, A.Zingoni, A.Soriani, B.Ricci, R.Molfetta, R.Paolini, A.Santoni, M.Cippitelli. Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells:role of DNA damage response activation. BMC Cancer 2015; 15:17; PMID:25609078; http://dx.doi.org/10.1186/s12885-015-1023-5
39. C.Fionda, G.Malgarini, A.Soriani, A.Zingoni, F.Cecere, M.L.Iannitto, M.R.Ricciardi, V.Federico, M.T.Petrucci, A.Santoni et al. Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells:role of STAT3. J Immunol 2013; 190:6662-72; PMID:23686482; http://dx.doi.org/10.4049/jimmunol.1201426
40. C.Fionda, A.Soriani, A.Zingoni, A.Santoni, M.Cippitelli. NKG2D and DNAM-1 Ligands:Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. Biomed Res Int 2015; 2015:178698; PMID:26161387; http://dx.doi.org/10.1155/2015/178698
41. A.Soriani, M.L.Iannitto, B.Ricci, C.Fionda, G.Malgarini, S.Morrone, G.Peruzzi, M.R.Ricciardi, M.T.Petrucci, M.Cippitelli et al. Reactive oxygen species- and DNA damage response-dependent NK cell activating ligand upregulation occurs at transcriptional levels and requires the transcriptional factor E2F1. J Immunol 2014; 193:950-60; PMID:24913980; http://dx.doi.org/10.4049/jimmunol.1400271
42. P.Falco, S.Bringhen, I.Avonto, F.Gay, F.Morabito, M.Boccadoro, A.Palumbo. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2007; 7:945-57; PMID:17627453; http://dx.doi.org/10.1586/14737140.7.7.945
43. I.R.Garrett, S.Dallas, J.Radl, G.R.Mundy. A murine model of human myeloma bone disease. Bone 1997; 20:515-20; PMID:9177864; http://dx.doi.org/10.1016/S8756-3282(97)00056-2
44. A.Ponzetta, G.Benigni, F.Antonangeli, G.Sciume, E.Sanseviero, A.Zingoni, M.R.Ricciardi, M.T.Petrucci, A.Santoni, G.Bernardini. Multiple myeloma impairs bone marrow localization of effector Natural Killer cells by altering the chemokine microenvironment. Cancer Res 2015; PMID:26438594; http://dx.doi.org/10.1158/0008-5472.CAN-15-1320
45. Y.Yang, S.Yaccoby, W.Liu, J.K.Langford, C.Y.Pumphrey, A.Theus, J.Epstein, R.D.Sanderson. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 2002; 100:610-7; PMID:12091355; http://dx.doi.org/10.1182/blood.V100.2.610
46. G.P.Dimri, X.Lee, G.Basile, M.Acosta, G.Scott, C.Roskelley, E.E.Medrano, M.Linskens, I.Rubelj, O.Pereira-Smith et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A 1995; 92:9363-7; PMID:7568133; http://dx.doi.org/10.1073/pnas.92.20.9363
47. Y.T.Bryceson, M.E.March, D.F.Barber, H.G.Ljunggren, E.O.Long. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med 2005; 202:1001-12; PMID:16203869; http://dx.doi.org/10.1084/jem.20051143
48. R.Testi, D.D'Ambrosio, R.De Maria, A.Santoni. The CD69 receptor:a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today 1994; 15:479-83; PMID:7945773; http://dx.doi.org/10.1016/0167-5699(94)90193-7
49. S.F.Ziegler, F.Ramsdell, M.R.Alderson. The activation antigen CD69. Stem Cells 1994; 12:456-65; PMID:7804122; http://dx.doi.org/10.1002/stem.5530120502
50. I.Mellman, G.Coukos, G.Dranoff. Cancer immunotherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
51. C.Michaloglou, L.C.Vredeveld, M.S.Soengas, C.Denoyelle, T.Kuilman, C.M.van der Horst, D.M.Majoor, J.W.Shay, W.J.Mooi, D.S.Peeper. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005; 436:720-4; PMID:16079850; http://dx.doi.org/10.1038/nature03890
52. P.G.Pelicci. Do tumor-suppressive mechanisms contribute to organism aging by inducing stem cell senescence? J Clin Invest 2004; 113:4-7; PMID:14702099; http://dx.doi.org/10.1172/JCI200420750
53. A.Banito, S.W.Lowe. A new development in senescence. Cell 2013; 155:977-8; PMID:24267881; http://dx.doi.org/10.1016/j.cell.2013.10.050
54. J.Campisi. Aging, cellular senescence, and cancer. Annu Rev Physiol 2013; 75:685-705; PMID:23140366; http://dx.doi.org/10.1146/annurev-physiol-030212-183653
55. T.W.Kang, T.Yevsa, N.Woller, L.Hoenicke, T.Wuestefeld, D.Dauch, A.Hohmeyer, M.Gereke, R.Rudalska, A.Potapova et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 2011; 479:547-51; PMID:22080947; http://dx.doi.org/10.1038/nature10599
56. W.Xue, L.Zender, C.Miething, R.A.Dickins, E.Hernando, V.Krizhanovsky, C.Cordon-Cardo, S.W.Lowe. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445:656-60; PMID:17251933; http://dx.doi.org/10.1038/nature05529
57. D.Z.de Back, E.B.Kostova, M.van Kraaij, T.K.van den Berg, R.van Bruggen. Of macrophages and red blood cells; a complex love story. Front Physiol 2014; 5:9; PMID:24523696; http://dx.doi.org/10.3389/fphys.2014.00009
58. S.Gasser, S.Orsulic, E.J.Brown, D.H.Raulet. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436:1186-90; PMID:15995699; http://dx.doi.org/10.1038/nature03884
59. H.Jung, B.Hsiung, K.Pestal, E.Procyk, D.H.Raulet. RAE-1 ligands for the NKG2D receptor are regulated by E2F transcription factors, which control cell cycle entry. J Exp Med 2012; 209:2409-22; PMID:23166357; http://dx.doi.org/10.1084/jem.20120565
60. A.Zingoni, F.Cecere, E.Vulpis, C.Fionda, R.Molfetta, A.Soriani, M.T.Petrucci, M.R.Ricciardi, D.Fuerst, M.G.Amendola et al. Genotoxic Stress Induces Senescence-Associated ADAM10-Dependent Release of NKG2D MIC Ligands in Multiple Myeloma Cells. J Immunol 2015; 195:736-48; PMID:26071561; http://dx.doi.org/10.4049/jimmunol.1402643
61. A.Sagiv, D.G.Burton, Z.Moshayev, E.Vadai, F.Wensveen, S.Ben-Dor, O.Golani, B.Polic, V.Krizhanovsky. NKG2D ligands mediate immunosurveillance of senescent cells. Aging (Albany NY) 2016. Feb; 8(2):328-44; PMID:26878797; http://dx.doi.org/10.18632/aging.100897
62. M.Serrano, A.W.Lin, M.E.McCurrach, D.Beach, S.W.Lowe. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997; 88:593-602; PMID:9054499; http://dx.doi.org/10.1016/S0092-8674(00)81902-9
63. R.S.Roberson, S.J.Kussick, E.Vallieres, S.Y.Chen, D.Y.Wu. Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 2005; 65:2795-803; PMID:15805280; http://dx.doi.org/10.1158/0008-5472.CAN-04-1270
64. C.A.Schmitt, J.S.Fridman, M.Yang, S.Lee, E.Baranov, R.M.Hoffman, S.W.Lowe. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002; 109:335-46; PMID:12015983; http://dx.doi.org/10.1016/S0092-8674(02)00734-1
65. T.K.Garg, S.M.Szmania, J.A.Khan, A.Hoering, P.A.Malbrough, A.Moreno-Bost, A.D.Greenway, J.D.Lingo, X.Li, S.Yaccoby et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica 2012; 97:1348-56; PMID:22419581; http://dx.doi.org/10.3324/haematol.2011.056747
66. X.Lu, Z.C.Ding, Y.Cao, C.Liu, T.Habtetsion, M.Yu, H.Lemos, H.Salman, H.Xu, A.L.Mellor et al. Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol 2015; 194:2011-21; PMID:25560408; http://dx.doi.org/10.4049/jimmunol.1401894
67. F.Debacq-Chainiaux, J.D.Erusalimsky, J.Campisi, O.Toussaint. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. Nat Protoc 2009; 4:1798-806; PMID:20010931; http://dx.doi.org/10.1038/nprot.2009.191
68. E.Parretta, G.Cassese, P.Barba, A.Santoni, J.Guardiola, F.Di Rosa. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005; 174:7654-64; PMID:15944266; http://dx.doi.org/10.4049/jimmunol.174.12.7654
69. A.Ponzetta, G.Sciume, G.Benigni, F.Antonangeli, S.Morrone, A.Santoni, G.Bernardini. CX3CR1 regulates the maintenance of KLRG1+ NK cells into the bone marrow by promoting their entry into circulation. J Immunol 2013; 191:5684-94; PMID:24184559; http://dx.doi.org/10.4049/jimmunol.1300090